Sermorelin (GRF 1-29)
Copy of the first 29 amino acids of GHRH
Experimental material. Read before using anything from here.
Nothing on this page is a medical recommendation, prescription or treatment plan. It is an organized translation of protocols circulating in research communities and, where it exists, of what published trials tested. The two are marked differently — and they are not equivalent.
Most of the compounds here have no FDA approval for human use. Several are sold labeled "research use only", which means they have not gone through purity, sterility or dosage controls for human consumption. A community-reported dose is not a validated dose: it is what someone reported having done.
Talk to a licensed health professional before considering any of these compounds. If you already use one and feel anything unexpected, seek care — do not wait for the next routine test.
Summary
Peptide that copies the first 29 amino acids of the body's natural GH-releasing hormone. Also called GRF 1-29 or sermorelin acetate. The short copy still fits the pituitary's GHRH receptor. It once had US approval as a diagnostic test, later withdrawn from the market.
Quick reference
- Common dose
- 200–300 mcg SC at night. Titration usually starts at 100 mcg.
- Half-life
- About 11–12 minutes. That is why it is nightly, not weekly.
- Reconstitution
- 3 mL of bacteriostatic water in a 10 mg vial gives 3 units per 100 mcg on the U-100.
- Timing
- 30–60 minutes before bed, on an empty stomach. Insulin and meals reduce the GH pulse.
Typical Titration Schedule
| Phase | Time | Dose nightly | Notes |
|---|---|---|---|
| Initiation | Weeks 1-2 | 100 mcg | Check for injection-site reactions and any sleep changes. |
| Standard | Weeks 3-4 | 200 mcg | Common starting therapeutic tier in practitioner protocols. |
| Optimization | Weeks 5-8 | 300 mcg | Often paired with IGF-1 and thyroid labs at the 6-week point. |
| Elevated | Week 9+ | 400-500 mcg | Higher end if response at 300 mcg is not enough. Watch IGF-1 trend. |
Sermorelin Timeline & What to Monitor
| Timepoint | What to check | Why |
|---|---|---|
| Baseline | IGF-1, full thyroid panel, fasting glucose, comprehensive metabolic panel | Establish starting values before therapy and rule out untreated hypothyroidism. |
| Week 2-4 | Subjective sleep quality, recovery, injection-site tolerance | Sleep changes are usually the first reported shift. |
| Week 6 | Repeat IGF-1, thyroid panel | First objective check on whether the protocol is producing a GH/IGF-1 response. |
| Week 12 | Repeat IGF-1, thyroid panel, body-composition markers if relevant | Mid-point on a 3-6 month cycle. |
| Month 6 | Full re-check of baseline labs plus body composition | Most modern practitioner protocols re-evaluate the cycle around this point. |
Storage and handling
The rules below apply to practically every lyophilized peptide in this reference. Where a compound has its own requirement, it appears in the table in the previous section.
- Lyophilized powder, sealed: refrigerator, between 2 and 8 °C, protected from light. Many tolerate room temperature for short transport periods, but that is tolerance, not a recommendation.
- After reconstitution: always refrigerated, between 2 and 8 °C. The stability window drops to days or a few weeks, depending on the compound.
- Never freeze after reconstituting. The freeze–thaw cycle degrades the peptide.
- Do not shake. Swirl the vial slowly. Shaking breaks the peptide chain.
- Bacteriostatic water down the wall of the vial, in a slow stream, not squirted directly onto the powder.
- Cloudy solution, with particles or a color change: discard. There is no recovery.
Lab tests and monitoring
This list is the one that appears recurrently in the source, with small variations by compound. It serves as a starting point for a conversation with a professional — not as a substitute for that conversation.
- Before starting: complete blood count, comprehensive metabolic panel, lipid panel, fasting glucose and HbA1c, TSH and free T4, blood pressure and resting heart rate.
- Depending on the compound: IGF-1 (GH axis), lipase and amylase (VIP and the incretin agonists), serum copper and ceruloplasmin (GHK-Cu and blends containing it), CRP.
- Reassessment: most protocols review between week 4 and week 8, and then every 8–12 weeks.
- Do not wait for the routine lab test in the face of abdominal pain, visual changes, a change in a mole, shortness of breath, asymmetric swelling or any new and persistent symptom. That is a reason to seek care, not a spreadsheet item.
Evidence limits
Data source: peptidedosingprotocols.com, accessed on September 3, 2026. Translation and organization in Portuguese are original work. No primary source (PubMed, trial registry, package insert) was checked in building this page — the check was against the secondary source, and that alone.